OncoMatch/Clinical Trials/NCT05901545
Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer
Is NCT05901545 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Panitumumab for head and neck squamous cell carcinoma.
Treatment: Panitumumab — This phase I trial tests the safety and effectiveness of indium In 111 panitumumab (111In-panitumumab) for identifying the first lymph nodes to which cancer has spread from the primary tumor (sentinel lymph nodes) in patients with head and neck squamous cell carcinoma (HNSCC) undergoing surgery. The most important factor for survival for many cancer types is the presence of cancer that has spread to the lymph nodes (metastasis). Lymph node metastases in patients with head and neck cancer reduce the 5-year survival by half. Sometimes, the disease is too small to be found on clinical and imaging exams before surgery. 111In-panitumumab is in a class of medications called radioimmunoconjugates. It is composed of a radioactive substance (indium In 111) linked to a monoclonal antibody (panitumumab). Panitumumab binds to EGFR receptors, a receptor that is over-expressed on the surface of many tumor cells and plays a role in tumor cell growth. Once 111In-panitumumab binds to tumor cells, it is able to be seen using an imaging technique called single photon emission computed tomography/computed tomography (SPECT/CT). SPECT/CT can be used to make detailed pictures of the inside of the body and to visualize areas where the radioactive drug has been taken up by the cells. Using 111In-panitumumab with SPECT/CT imaging may improve identification of sentinel lymph nodes in patients with head and neck squamous cell cancer undergoing surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage ANY T STAGE
Subjects diagnosed with any T stage, any subsite within the head and neck
Lab requirements
Blood counts
Hemoglobin ≥ 9 gm/dL; white blood cell count > 3000/mm^3; platelet count ≥ 100,000/mm^3
Kidney function
serum creatinine ≤ 1.5 times upper reference range; severe renal disease or anuria excluded
Liver function
significant liver disease excluded; liver function must be acceptable
Cardiac function
myocardial infarction, cerebrovascular accident, uncontrolled congestive heart failure, or unstable angina within 6 months excluded
Have acceptable hematologic status, kidney function, and liver function including the following clinical results: Hemoglobin ≥ 9 gm/dL; White blood cell count > 3000/mm^3; Platelet count ≥ 100,000/mm^3; Serum creatinine ≤ 1.5 times upper reference range. Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. Severe renal disease or anuria.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Vanderbilt University/Ingram Cancer Center · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify